Goal: To assess physicians’ practice patterns in diagnosis, management, and knowledge of emerging treatments for postpartum depression (PPD)
• A 27-question clinical practice assessment survey was made available online on March 27, 2018 without monetary compensation or charge, and data were collected until June 5, 2018
• Responses were de-identified and aggregated prior to analyses to maintain confidentialityResults:Data were collected for the 1024 psychiatrists, 188 obstetricians/gynecologists (ob/gyns), and 193 primary care physicians (PCPs).
• 10% or less reported being very confident in treating patients with PPD• Pathophysiology: 50% of psychiatrists, 43% of ob/gyns, and 46% of PCPs were aware the role of allopregnanolone in the development of PPD
• Risk factors: 51% of psychiatrists, 59% of ob/gyns, and 45% of PCPs were aware the most common risk factors for PPD
• Screening: 46% of psychiatrists, 31% of ob/gyns, and 30% of PCPs ask clinical questions and do not use validated tools/scales, and 7% of psychiatrists, 10% of ob/gyns, and 17% of PCPs do not screen for PPD at all
• Management: On average, 63% of psychiatrists, 50% of ob/gyns, and 52% of PCPs were able to tailor appropriate treatments for PPD
• Awareness on emerging treatments: 9% of psychiatrists, 11% of ob/gyns, and 5% of PCPs were aware of the clinical data on emerging treatments for PPDConclusions: This educational research yielded important insights into clinical practice gaps in PPD, indicating that multiple specialists would benefit from education to better screen and manage PPD.